Compare Infosys Limited (INFY) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Teladoc Health Inc — how do they compare? Infosys Limited trades at $10.84 (market cap $41.74B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Infosys Limited is far larger — about 41.3× Teladoc Health Inc's market cap, and Infosys Limited pays a 4.89% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Teladoc Health Inc for 39 Days on average.
| INFY | TDOC | |
|---|---|---|
Market Cap | $41.74B | $1.01B |
Volume | 31,354,285 | 4,668,477 |
Sector | Technology | Health |
52-Week High | $20.22 | $9.72 |
52-Week Low | $10.49 | $4.47 |
Typical Hold Time | 27 Days | 39 Days |
Enterprise Value | $39.48B | $1.27B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.
The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
